MXPA01002240A - Tratamiento selectvio de receptores de somatostatina endoteliales. - Google Patents

Tratamiento selectvio de receptores de somatostatina endoteliales.

Info

Publication number
MXPA01002240A
MXPA01002240A MXPA01002240A MXPA01002240A MXPA01002240A MX PA01002240 A MXPA01002240 A MX PA01002240A MX PA01002240 A MXPA01002240 A MX PA01002240A MX PA01002240 A MXPA01002240 A MX PA01002240A MX PA01002240 A MXPA01002240 A MX PA01002240A
Authority
MX
Mexico
Prior art keywords
selective treatment
somatostatin receptors
endothelial
endothelial somatostatin
receptors
Prior art date
Application number
MXPA01002240A
Other languages
English (en)
Inventor
York Hsiang
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of MXPA01002240A publication Critical patent/MXPA01002240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MXPA01002240A 1998-09-01 1999-09-01 Tratamiento selectvio de receptores de somatostatina endoteliales. MXPA01002240A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002246791A CA2246791A1 (en) 1998-09-01 1998-09-01 Treatment of endothelium with somatostatin analogues
PCT/CA1999/000800 WO2000012111A2 (en) 1998-09-01 1999-09-01 Selective treatment of endothelial somatostatin receptors

Publications (1)

Publication Number Publication Date
MXPA01002240A true MXPA01002240A (es) 2003-08-20

Family

ID=4162807

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01002240A MXPA01002240A (es) 1998-09-01 1999-09-01 Tratamiento selectvio de receptores de somatostatina endoteliales.

Country Status (10)

Country Link
US (2) US20020137676A1 (es)
EP (1) EP1107780A2 (es)
JP (1) JP2002523465A (es)
CN (1) CN1320042A (es)
AU (1) AU769289B2 (es)
CA (1) CA2246791A1 (es)
MX (1) MXPA01002240A (es)
NO (1) NO20011025L (es)
NZ (1) NZ510543A (es)
WO (1) WO2000012111A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040837A3 (en) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
CA2433785C (en) * 2001-01-12 2009-08-04 Michael Dewitt Culler Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
US20040198653A1 (en) * 2001-06-25 2004-10-07 Culler Michael De Witt Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof
US20030207811A1 (en) * 2002-05-03 2003-11-06 Schrier Bruce K. Method of treating retinopathy of prematurity using somatostatin analogs
EP1367397A1 (en) * 2002-05-29 2003-12-03 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with somatostatin receptor 1 (SSTR1)
EP1369697A1 (en) * 2002-06-07 2003-12-10 Bayer Ag Diagnostics and therapeutics for diseases associated with somatostatin receptor 4 (SSTR4)
AU2003259172A1 (en) * 2002-07-24 2004-02-09 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
KR20050059319A (ko) * 2002-10-31 2005-06-17 센주 세이야꾸 가부시키가이샤 각막 장해 치료제
AU2004273986B2 (en) 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
WO2005041901A2 (en) * 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Therapeutics using somatostatin agonists
WO2005082844A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Treatment of diseases by using a somatostatin receptor agonist
WO2005082845A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Novel therapies with somatostatin receptor agonists
GB0425258D0 (en) * 2004-11-16 2004-12-15 Novartis Ag Organic compounds
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
US8226949B2 (en) * 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
BRPI0717135B8 (pt) 2006-10-16 2021-05-25 Salk Inst Biological Studies antagonista peptídico cíclico de somastotatina e composição farmacêutica
JP2010513526A (ja) * 2006-12-22 2010-04-30 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
WO2010075332A1 (en) * 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
WO2010120506A1 (en) * 2009-03-31 2010-10-21 Ordway Research Institute, Inc. Combination treatment of cancer with cetuximab and tetrac
CA2765792C (en) * 2009-06-17 2017-03-28 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2011151782A1 (en) 2010-06-02 2011-12-08 Preglem Sa A role for somatostatin to modulate initiation of follicular growth in the human ovary
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
AU2017279536A1 (en) 2016-06-07 2018-12-20 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αvβ3 integrin thyroid antagonists
AU2018230429B2 (en) 2017-03-09 2023-06-15 Corcept Therapeutics, Inc. Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
JP7099717B2 (ja) * 2019-09-30 2022-07-12 株式会社理研バイオ ソマトスタチン受容体
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
US4904642A (en) * 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
US5174859A (en) * 1990-04-11 1992-12-29 Hpd Incorporated Method for treating mechanical pulp plant effluent
US5409894A (en) * 1991-03-14 1995-04-25 Sandoz Ltd. Method of preventing balloon catheterization blood vessel damage
US6001960A (en) * 1992-09-01 1999-12-14 The Trustees Of The University Of Pennsylvania Synthetic somatostatin mimics
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
TW357143B (en) * 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
AU2764797A (en) * 1996-05-14 1997-12-05 Novo Nordisk A/S Somatostatin agonists and antagonists
ATE214604T1 (de) * 1997-06-24 2002-04-15 Novo Nordisk As Verwendung von somatostatin agonisten und antagonisten zur behandlung von augenkrankheiten
US6124256A (en) * 1998-03-27 2000-09-26 Haeyry; Pekka Method for the prevention of a patient's fibroproliferative vasculopathy

Also Published As

Publication number Publication date
CA2246791A1 (en) 2000-03-01
AU769289B2 (en) 2004-01-22
US20020137676A1 (en) 2002-09-26
CN1320042A (zh) 2001-10-31
NO20011025L (no) 2001-03-30
AU5499799A (en) 2000-03-21
NZ510543A (en) 2004-01-30
JP2002523465A (ja) 2002-07-30
NO20011025D0 (no) 2001-02-28
US20060089299A1 (en) 2006-04-27
EP1107780A2 (en) 2001-06-20
WO2000012111A2 (en) 2000-03-09
WO2000012111A3 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
MXPA01002240A (es) Tratamiento selectvio de receptores de somatostatina endoteliales.
IL125592A0 (en) Water treatment
AU140490S (en) Action trooper
IL150033A0 (en) Selective neurokinin antagonists
ZA200108446B (en) Novel method of treatment.
GB9800942D0 (en) Well treatment
GB9907812D0 (en) Sequencing
ZA200204156B (en) Water treatment.
GB9823659D0 (en) Water treatment
GB9901588D0 (en) Water treatment
ZA200007396B (en) Method of treatment.
GB9702964D0 (en) Water treatment
GB9703075D0 (en) Water treatment
GB9815497D0 (en) Treatment
GB9818524D0 (en) Inorgasmia treatment
EP1143998A4 (en) TREATMENT OF HYPERTENSION
GB2350358B (en) Water treatment
ZA994585B (en) Treatment of water.
GB9828550D0 (en) Treatment
ZA995637B (en) Anchoring.
AU1167P (en) Treat xTriticosecale
PL352217A1 (en) Selective iglur5
HK1062474A1 (en) Method of purifying b-secretase.
ZA994586B (en) Treatment of water.
ZA994584B (en) Treatment of water.